SCHEMBL5580201

SCHEMBL5580201

NC(Cc1ccc(O)cc1Cl)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.55
ALOX15 P16050 4/20 0.55
HSD17B10 Q99714 4/20 0.55
CYP3A4 P08684 3/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
NFKB1 P19838 2/20 0.55
BLM P54132 2/20 0.55
PMP22 Q01453 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
ADORA3 P0DMS8 2/20 0.55
HTR2A P28223 2/20 0.55
TSHR P16473 2/20 0.55
HTR1A P08908 1/20 0.55
HTR2C P28335 1/20 0.55
SLC6A4 P31645 1/20 0.55
HTR7 P34969 1/20 0.55
HTR2B P41595 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5580203 1.00 KMT2A (0.55) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL15085673 1.00 KMT2A (0.55) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL7276720 0.85 KMT2A (0.46) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL25578544 0.85 HDAC8 (0.48) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL29350881 0.85 HDAC8 (0.58) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL44905 0.85 HDAC8 (0.58) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL44904 0.85 HDAC8 (0.58) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL1613174 0.85 HDAC8 (0.58) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL28075883 0.84 CYP3A4 (0.47) KMT2AALOX15HSD17B10CYP3A4KDM4E
SCHEMBL4140820 0.83 KDM4E (0.66) KMT2AALOX15HSD17B10CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382646-A1 ENGINEERED ENZYMES AND METHODS FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-12-18 US claimed
US-12421534-B2 Engineered enzymes and method for the synthesis of diverse tyrosine analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-09-23 US claimed
US-20230313245-A1 Engineered Enzymes and Method for the Synthesis of Diverse Tyrosine Analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-10-05 US claimed
WO-2023086520-A2 ENGINEERED ENZYMES AND METHOD FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-05-19 WO claimed
US-20250382646-A1 ENGINEERED ENZYMES AND METHODS FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-12-18 US disclosed
US-12421534-B2 Engineered enzymes and method for the synthesis of diverse tyrosine analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-09-23 US disclosed
US-20230313245-A1 Engineered Enzymes and Method for the Synthesis of Diverse Tyrosine Analogs CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-10-05 US disclosed
WO-2023086520-A2 ENGINEERED ENZYMES AND METHOD FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-05-19 WO disclosed
EP-3655036-A1 COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS Hoffman Technologies, Inc. (US) 2020-05-27 EP disclosed
CN-110769855-A Compositions and methods for treating retinopathy 史蒂文·霍夫曼 2020-02-07 CN disclosed
WO-2019018633-A1 COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS HOFFMAN TECHNOLOGIES, INC. (US) 2019-01-24 WO disclosed
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2006017619-A2 RECEPTOR-BINDING CYCLIC PEPTIDES AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-02-16 WO disclosed
US-20060029544-A1 Receptor-binding cyclic peptides and methods of use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060029544-A1 Receptor-binding cyclic peptides and methods of use ITGB3, ITGB5, ITGA5 KMT2A 4001/4885ALOX15 3927/4885HSD17B10 4773/4885
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 KMT2A 3586/4885ALOX15 4182/4885HSD17B10 4778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.